Article
Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic model.
Drug metabolism and disposition: the biological fate of chemicals - 1 Jun 2015
Steere Boyd, Baker Jessica A Roseberry, Hall Stephen D, Guo Yingying
Abstract excerpt
It is important to examine the cytochrome P450 2C19 (CYP2C19) genetic contribution to drug disposition and responses of CYP2C19 substrates during drug development. Design of such clinical trials requires projection of genotype-dependent in vivo clearance and associated variabilities of the investigational drug, which is not generally available during early stages of drug development, but is essential for CYP2C19...
Topics
Join the communities discussing this publication.